All BC tissues were classified as IDC, 5 of which (CZ016, CZ019-022) were treatment-naïve, ER+, PR+, and HER2- while one (CZ017) was PR-/HER2- with low expression of ER and underwent neoadjuvant therapy prior to surgery (Fig. S1H). This evidence concerns the gene ESR1 and breast cancer.